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AROMEAbstract Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new vi-
rus that has never been identified in humans before. COVID-19 caused at the time of writing
of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including
two-third in Europe. In this context, Oncology Departments of the affected countries had
to adapt quickly their health system care and establish new organizations and priorities. Thus,
numerous recommendations and therapeutic options have been reported to optimize therapy
delivery to patients with chronic disease and cancer.
Obviously, while these cancer care recommendations are immediately applicable in Europe,
they may not be applicable in certain emerging and low- and middle-income countries
(LMICs). In this review, we aimed to summarize these international guidelines in accordance
with cancer types, making a synthesis for daily practice to protect patients, staff and tailor
anti-cancer therapy delivery taking into account patients/tumour criteria and tools availabil-
ity. Thus, we will discuss their applicability in the LMICs with different organizations, limited
means and different constraints.
ª 2020 Elsevier Ltd. All rights reserved.
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Coronavirus disease 2019 (COVID-19) is an infectious
disease caused by a new virus that has never been
identified in humans before. This virus causes respira-
tory illness with symptoms like cough, fever and, in most
severe cases, pneumonia. At the time of writing of this
article, 2.5 million cases of infections have been reported
in 193 countries with 165,000 deaths, including Two-
third in Europe in accordance with the applied case
definitions and testing strategies in the affected coun-
tries. This pandemic surprised the whole world by its
contagiousness, with a high speed of diffusion in all
subpopulations and its violence in terms of deaths.
The Oncology Departments of the affected countries
had to adapt quickly and establish new organizations
with a practical definition of priorities. Thus, numerous
recommendations and therapeutic options have been
developed to allow the optimization of departments’
organization and function in order to provide and
continue to deliver optimal therapy to all patients with
cancer.
In these exceptional circumstances, many groups
and scientific societies have made practical recom-
mendations. In Europe, the first recommendations
concerned mainly the way of protecting patients with
cancer [1]. Since then, many guidelines have been pro-
posed for different types of cancers. Obviously, this
type of recommendation immediately applicable in
Europe may not be applicable in certain emerging
countries or low- and middle-income countries
(LMICs). Thus, it seemed fundamental to us to sum-
marize these international guidelines according to
cancer types and to make a synthesis for daily practice.
In addition, we aimed to discuss their applicability in
the LMICs with different organizations, limited means
and different constraints.Table 1
Survey from the French oncology societies and clinical research groups.
Type of cancer Name of the society/group(references) Re
Head and neck GORTEC [30,31] Ye
Lung GOLF [32,33]
Breast Saint Paul-de-Vence [35] Ye
Gynaecological GINECO No
SCGP and FRANCOGY [36] Ye







Radiation oncology SFRO [39] Ye
GI, gastrointestinal; GORTEC, Groupe d’Oncologie Radiothérapie Tête
American Society of Breast Surgeons; SCGP, Société de Chrurgie Gynéc
Urinaires; CCAFU, Comité de Cancérologie de l’Association Françasie d
logie; SNFGE, société nationale francaise de gastro-enterologie; APHP, A
cologie Radiothérapie. ESMO, European Society of Medical Oncology.2. Material and methods
To collect the French data, we sent an e-mail to the
French Oncology Societies that had not reported
guidelines for COVID-19 crisis between March 1st and
April 30th. The responses are summarized in Table 1.
For the international literature data, a search in
PubMed was performed using the following key words:
‘COVID-19 and oncology’, ‘COVID-19 and cancer’,
‘COVID-19 and radiotherapy’ (RT), ‘COVID-19 and
guidelines for cancer’, ‘COVID-19 and recommenda-
tions for cancer’. All abstracts and articles in English
were collected. Articles in Chinese without English ab-
stracts were not included in the review. In Fig. 1, we
summarized the literature search and references that are
included in this review. In summary, articles related to
oncology guidelines and organization were selected
based on the search using the following keywords:
- For ‘COVID-19 and oncology’: Among the 78 articles, 9
were related to either guidelines/recommendations (n Z 5)
[1e5] or medical and health system organization (n Z 4)
[6e9].
- For ‘COVID-19 and cancer’: Among the 134 articles, 12
were related to either guidelines/recommendations (n Z 6)
[10e15] or medical and health system organization (n Z 6)
[16e22].
- For the last 3 key words, namely ‘COVID-19 and radio-
therapy’ (n Z 13) [23e29], ‘COVID-19 and guidelines for
cancer’ and ‘COVID-19 and recommendations for cancer’,
the 21 additional references found were redundant and were
found with the first two searches (Fig. 1).
All recommendations, including guidelines for RT
practice (23-29), have been finally summarized in tables
and discussed via e-mails with the AROME and
TRONE networks members regarding their applica-










s International radiation therapy network [22]
Et Cou; GOLF, Groupe d’Oncologie de Langue Française; ASBS,
ologique et Pelvienn; GETUG, Groupe d’Etude des Tumeur genito-
’Urologie; GERCOR, groupe coopérateur multidisciplinaire en onco-
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Fig. 1. Results of the literature screening, selection process of articles and keywords.
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3.1. Patient visits, staff and departments organization
(Table 2)
Patients with cancer are more susceptible to infection
than individuals without cancer because of the immu-
nosuppressive effect induced by and anti-cancer therapy.
In the context of a global public health emergency
related to the emergence of COVID-19, it is essential to
protect patients and staff to ensure continuity of care.
Thus, a major reorganization of our departments was
needed to adapt the resources for oncology care main-
tenance to ensure timely and proportionate imple-
mentation of contingency plans that balance risks and
protect patients and healthcare workers during the in-
fections rise period. Moreover, the departments reor-
ganization must take into account specifics of the
specialities involved in the management of patients with
cancer.3.2. Surgical oncology departments
For surgery, two situations are to be distinguished: pa-
tients having undergone surgery just before the COVID-
19 outbreak and patients whose surgery is already or
must be planned during this period. In the first case, it is
reported that COVID-19epositive patients are likely to
be at higher risk of clinically severe events than those
who did not have surgery. Thus, protective measures
must be reinforced and their visits to the department
limited. The emergency for adjuvant treatments delivery
should be discussed on a case-by-case basis. For
scheduled surgery, the discussion will focus on thedelayed interventions, taking into account the benefit/
risk ratio for each patient.
In Table 2 some recommendations are presented,
from our group (AROME) and others, regarding the
prioritization of urgent surgeries and the need to work
with the hospital to ensure that adequate supplies (PPE,
staffing, and bed capacity) will be available for non-
elective, time-sensitive surgeries. Delayed oncologic
surgeries may lead to disease progressions and result in
tumours that are no longer resectable, leading to worse
survival outcomes. Thus, all decisions for delayed
surgery  shift to neoadjuvant therapies should be taken
in the frame of multidisciplinary board meetings.3.3. Radiation oncology departments
In RT departments, staff must also be protected against
COVID-19 at all times. Weekly or daily team rotation
and dedicated routes for positive COVID-19 patients
taken in dedicated time slots with full protection of staff
is a prerequisite to reduce the risk to staff and non-
infected patients. Tables 2 and 3 show the main reported
global and specific recommendations.
In Table 3, we present the main recommendations for
workers in RT departments and staff organization, in
accordance with available human resources. In addition,
scenarios taking into account the reduction in the
number of workers in case of COVID-19 infection have
been proposed to ensure treatment with the required
quality and safety.
For patients, a distinction must be made between
patients who have started treatment and those who have
not yet started irradiation. For the first, finishing treat-
ment is a priority, either following initial planned frac-
tionation schedules or after plan recalculation to shorten
Table 2
Recommendations for departments organization and procedures for patients, visitors and staff.





Dedicated areas in oncology
and radiotherapy
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Switch IV treatment to oral drugs
when possible




Open space out patients
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expectancy, age, line therapy
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Integrate all best-practice























Separate Entrance/exit Maintain therapy schedule
according to the benefit risk and
availability of means for locally
advanced and high-risk, patients








Should be limited Staff COVID-
19 þ out of planning
and self isolation 14
days
Space with limited patients
in waiting room
Deep remission (3e6 months)





patients outside of cancer
center or dedicated area
COVID-19, coronavirus disease 2019.
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and phone calls could be advocated to limit the time
spent in the hospital every day. For COVID-19epositive
patients, dedicated areas, separate exit/entrance and
dedicated time slots have to be planned.
For patients who have not started RT yet, priorities
should be also fixed as per tumour sites, adjuvant or
neoadjuvant settings, the possibility of delaying irradi-
ation in settings where primary chemotherapy or endo-
crine therapy could be administrated. These situations
will be discussed in the next section.3.4. Medical oncology departments
As for other departments, dedicated areas, specific exits/
entrance and a limited number of patients in the waiting
rooms are recommended to limit contacts between
infected and non-infected patients. To ensure minimal
presence in the hospital, some regimens can be altered to
minimize infusion visits or a switch to oral drugs when
possible. During treatments, systematic screening before
appointments is recommended by the majority of
experts.
Table 3
Radiation Oncology departments organization during COVID-19 pandemic period.
Recommendations for radiotherapy departments organization
Societies/groups/teams Frenche RO society [39] Simcock et al. [22] Applicability in LMICs
March 19th March 20th
Workers protection
WHO guidelines for preventive measures and use of Personal
Protection Equipment (PPE)
X X Applicable
Reduction of the number of health professionals in radiotherapy
departments to the minimum required, promoting teleworking
X X Teleworking
probably not
Inviting the local Infection Control department X
Temperature monitoring for all patients X Applicable
Special monitoring for ‘contact’ patients (those who had close contact
with confirmed COVID cases)
X Probably not
Symptomatic health professional: PCR, isolation, adapted care X Probably not
Department Organization
Delay of follow-up medical examinations X Applicable
Remote/telephone consultation when possible X X Probably not
Minimize number of additional visitors, family members or careers X Applicable
Reorganization of waiting rooms (separating fragile vs potentially
infected patients, increased distances, removal of infection vectors)
X X
Optimize department areas for decontamination X
Model for estimation of the harms of COVID infection for cancer
patients
X
Creating capacity by reducing fraction numbers X
Separation of fragile/immunocompromised vs infected/contact patients X
Special protocol for infected/contact patients (treatment pause or
dedicated treatment timeslot)
X X
When Insufficient Number Of Health Professionals
Priority to: primary radiation treatments (vs operable or adjuvant),
curative (vs palliative)
X X Applicable
Delay treatment for hormone-sensitive cancersa X
Record all changes in treatments X
Only one therapist per treatment (standard) X
Two therapist per treatment (complex treatments) X
Turnover for radiation oncologists and medical physicist X
Brachytherapy
Delay of all brachytherapy treatments X Applicable
Prefer local/spine anaesthesia to general anaesthesia X
Delay of treatments where surveillance is an alternative option X
Priority to: primary treatments (vs adjuvant), single treatment (vs
fractionated)
X
FFP2 masks for head and neck treatments X
Special cases dealt with
Insufficient number of medical physicists X Applicable
Insufficient number of radiation oncologists X
Increase of quality control hours and prioritization of checks X
Specific indications for omitting/delaying/hypofractionating/pausing
radiotherapy treatment by cancer type and curative vs palliative
treatment
X
COVID-19, coronavirus disease 2019; LMICs, low- and middle-income countries.
a With attention on a post-crisis unmanageable surge in activity. RO: radiation oncology.
Y. Belkacemi et al. / European Journal of Cancer 135 (2020) 130e146 135For patients already in deep remission (stable for
more than 6e12 months), stopping or delaying treat-
ment may be an option. A temporary break could be an
option for patients with slowly evolving metastases. For
all patients on active anti-cancer therapy, we need to
remain vigilant for COVID-19 symptoms. Their therapy
should be planned in a dedicated area.
Changes in management strategy and therapy in
accordance with type of cancer (Table 4).3.4.1. Head and neck cancer
The medical complexity of head and neck cancer man-
agement may lead to prolonged delays that worsen
treatment outcomes. Therefore, those caring for patients
with head and neck cancer must take action to reduce
these negative impacts as the country rallies to overcome
the challenges posed by this pandemic [24]. Thus, ther-
apeutic adaptation possibilities reported by the French
groups are based mainly on expert opinion [30,31].
Table 4
Approach to curative intent therapy by tumour sites: summary of the published recommendations during COVID-19 crisis.
Disease Criteria for delay Fractionation Boost Systemic therapy References LMIC applicability
Head and neck
Head and neck
cancer: all tumour sites
Head and neck cancer treatment
break or deferral may
lead to reduced tumour control
Consider mitigatinsbg with
additional radiation dose after
treatment or addition of chemotherapy.
[30.31] Applicable
Patients < 70 y, with non
resectable tumours:
Standard time for
treatment  4 weeks since
diagnosis should be respected
SIB should be considered:
-69,96Gy/54.45 in 33 fractions
-69Gy/55 in 30 fractions
Consider published hypofractionated





should be offered according




(such as larynx T1 N0),
hypofractionation using




the first 2 months before
combined chemoradiation
Patients <70 y, eligible
for adjuvant RT:
A period of 6e8 weeks between
surgery and RT should be respected.
-R1 and/or extra-capsular rupture:
66 Gy/54 Gy in conventional fractionation,
-otherwise 60 Gy or 50 Gy depending







Patients >70 years old or unfit
(PS 2 and/or with
significant comorbidities)
Non resectable tumours:
-30 Gy in 10 fractions
-10e12 days later: 25 Gy in 10
fractions or 24 Gy in 8 fractions
Adjuvant:
-SIB: 51Gy/42.5 in 17 fractions or
any other hypofractionated schedules
Applicable for palliative
care
HPV no de-escalation for HPV þ tumours Not applicable
Lung cancer
Early NSCLC No delay of post-op RT
No immediate RT for N2 NSCLC
Standard RT Standard therapy








Locally advanced NSCLC No delay of CRT Standard RT Standard therapy
- Carboplatin is preferred over cisplatin
- DURVALUMAB: double dose/4 weeks
Not applicable
Metastatic NSCLC PS 1, Fit patients
PS 2, elderly patients
Palliative strategy Oncogenic alteration: standard therapy
No oncogenic alteration:
 4 cycles of CT/Immunotherapy
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indication of nodal RT
Delay surgery
by 3e6 months
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[38, 39]
Surgery should
be switched to RT
Post-operative or
“rising PSA” RT indication
Delay RT by 3 months 3 mon s of
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Castration-resistant patients Delay/avoid CT
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[38, 39] Hypofractionation only
if IMRT is available a

































































Table 4 (continued )
Disease Criteria for delay Fractionation Boost Systemic therapy References LMIC applicability
be preferred (55Gy in 20fr)
Metastatic 1st line cisplatin-gemcitabine þ G-CSF
(No MVAC)
[38] Applicable
If G-CSF is available
Metastatic 2nd line Delay treatment Unknown impact of
checkpoint inhibitors on covid19
e
GI e oesophagus
Localized cancer RTCT with
Carboplatin-Taxol
Standard [40e47] Applicable
Inoperable or advanced Standard Or FOLFOX
Complete response to CRT Follow-up or
delay surgery
Incomplete response to CRT Delay salvage surgery
up to 3 months
GI-Pancreas
Operable/bordrline Patients who does
not fit for neo-adjuvant
chemotherapy
should be considered as
high priority for surgery
NA FOLFOX
to delay surgery
[40, 47] Applicable according
to drugs availability







should be also considered
as a high priority
CT with schemes
using Capecitabine
Post-operative setting Delay adjuvant treatments







CRT completed or ongoing Delay surgery up to 3 months [40, 42e44] Applicable
All new patients Pre operative RT 25Gy in 5fr and
surgery after 3 months





Tumour excision or watch
and wait (GRECCAR 2 criteria)
GI e Anal canal
Localized Standard
chemo-radiation based on
























































Cervical cancer -No delay of RT or RCT
-Delay of LN staging surgery
-No RT in the in case
of complete response
Standard RT or RCT [36, 37] Applicable
Gynaecological e Endometrium
Low and intermediate
risk or stage IA
Delay surgery







High-risk or stage II - To favour the
MSKCC algorithm




- Delay of RT according
to the benefit/
Consider if brachytherapy















Vulvar cancer Early-stage: surgery could




Vaginal cancer To favour imaging
for staging in order to
omit LN surgery
RTCT if no surgery
indication without delay
Ovarian Early-stage: delay
surgery up to 1e2 months
Advanced stage: to




RTCT, radiochemotherapy RT, radiotherapy; NA, neoadjuvant; LN, lymph nodes; COVID-19, coronavirus disease 2019; LMICs, low- and middle-income countries; MSKCC: Memorial Sloan
















































Y. Belkacemi et al. / European Journal of Cancer 135 (2020) 130e146140Thus, in daily practice, any adaptation must be dis-
cussed with the patient and in the frame of multidisci-
plinary board meetings. For surgery community, the
aim is to minimize the risk of care opportunity loss for
patients and to anticipate the increased number of
cancer patients to be treated at the end of the pandemic,
taking into account the degree of urgency, the difficulty
of the surgery, the risk of contaminating the caregivers
(tracheotomy) and the local situation (whether or not
the hospital and intensive care departments are over-
stretched) [30,31].
All indications for combined chemoradiotherapy
must be maintained, as well as the usual delays between
diagnosis and RT (4 weeks) or between surgery and
RT (6e8 weeks). Fractionation must be optimized:
favour hypofractionation (early-stage larynx, elderly or
comorbid patients) and simultaneous integrated boost
[30].
3.4.2. Lung cancer
Following the ESTRO (European society of therapeutic
radiation oncology)-ASTRO (American society of
therapeutic radiaion oncology) consensus statement
[32] and the French recommendations [33], we need to
distinguish recommendations according to pathology
and stage of the disease.
For early nonesmall-cell lung cancer, surgery could
be delayed up to 6 weeks for stage I II, N0 disease.
Another alternative approach is to deliver stereotactic
RT with a limited number of fractions (1 to 3).
In the post-operative setting, patients undergoing
treatment have to complete their program. For adjuvant
RT, given the uncertainty about its impact in this
context, it is not recommended to initiate RT for pa-
tients with N2 disease.
In locally advanced nonesmall-cell lung cancer, pa-
tients are more at risk of developing severe respiratory
acute complications requiring intensive care. Thus, only
patients who are already undergoing therapy should
complete their program while initiation of RT in new
patients is discussed in the frame of multidisciplinary
bord meetiings. For patients undergoing chemotherapy,
carboplatin is preferred over cisplatin for its rapidity of
administration and its lower toxicity.
The administration of durvalumab must be carried
out if the safety conditions are reasonable, by adapting
the treatment regimen [33].
3.4.3. Breast cancer
The American Society of Breast Surgeons (ASBS) [34],
the French Saint Paul-de-Vence (SPDV) group [35] and
the international RT network [3] reported their recom-
mendations in March. The ASBS recommended
breaking into three priority categories based on patient
conditions, ranging from immediately life-threatening
conditions to patients stable enough that services can
be delayed for the duration of the COVID-19 pandemic.In the SPDV conception, different scenarios were
detailed.
In summary, for post-operative patients and those on
follow-up telemedicine is recommended. Interventions
for biopsies in abnormal mammograms, neoadjuvant
patients finishing treatment, hormone therapy during
6e12 months for luminal hormone receptor (HR)-pos-
itive patients, adjuvant antibody treatment reasonably
be curtailed after 7 months instead of 12 months of
treatment for HER2-positive and limit reconstructive
surgery to expander only are the main recommenda-
tions. In addition, more specifically in patients with
breast luminal cancer (early or locally advanced) pri-
mary endocrine treatment could safely delay surgery up
to 3 to 6 months, in a ccoradnce with several published
trials.
For adjuvant RT, up to 16 weeks of last surgery or
chemotherapy with high-risk indications for radiation,
such as inflammatory disease, node positive disease,
triple negative breast cancer, post-neoadjuvant chemo-
therapy with residual disease at surgery, young age
(<40) with additional high-risk features, are
recommended.
Patients older than 65e70 y with lower risk stage I
HR-positive/HER2- negative cancers and ductal carci-
noma in situ (DCIS), adjuvant endocrine therapy can be
encouraged to defer/omit radiation without affecting
overall survival. Hypofractionated regimens are recom-
mended, including in cases of DCIS, post-mastectomy
or nodal RT. The boost is reserved for high-risk pa-
tients, and SIB or hypofractionation is to be preferred
[3,22,29,35].
3.4.4. Gynaecological cancers
Since the beginning of March, numerous scientific so-
cieties and research groups provided recommendations
for cervical, endometrial and ovarian cancer [36,37].
In summary, for cervical cancer, it has been suggested
that the value of lymph node staging surgeries must be
reviewed on a case-by-case basis in accordance with
comorbidities, imaging results and stage of disease. For
therapy, the recommendation is to omit any changes in
radiochemotherapy regimens or interrupt or postpone
RT that could lead to tumour response reduction. After
concomitant radiochemotherapy, surgery should not be
systematic in cases of complete response.
In endometrial cancer, recommendations are in
accordance with the stage of disease [36]. Surgery re-
mains the standard of care for early-stage disease. The
minimally invasive laparoscopic approach, robot-
assisted (or not) is the preferred approach. For low
and intermediate pre-operative European society of
medical oncology (ESMO) risk, total hysterectomy with
bilateral ovariectomy associated with a sentinel node
procedure should be preferred. It is lawful to consider
postponing surgery by 1e2 months in low-risk endo-
metrial cancers. For high ESMO risks involving staging
Y. Belkacemi et al. / European Journal of Cancer 135 (2020) 130e146 141by pelvic and lumbo-aortic nodal dissection, it seems
recommended to favour the Memorial Sloan Kettering
Cancer Center (MSKCC) algorithm, associating posi-
trons emission tomography - computed tomography
(PET-CT) and sentinel node biopsy procedure to omit
nodal dissection which increases the risk of pre- and
post-operative complications.
For ovarian cancers, recommendations are as per the
stage of disease. For early-stage ovarian cancer, surgery
may be postponed by 1e2 months, whereas for
advanced disease, neoadjuvant chemotherapy or pri-
mary ‘debulking’ surgery should be considered. In cases
of neoadjuvant chemotherapy, additional cycles up to 6
could be considered before surgery [36].
For vulvo-vaginal cancers, the main messages consist
of delaying surgery by 1e2 months and indicate che-
moradiation in locally advanced cases, whereas PET-CT
for staging should be favoured to delay lymph node
dissection.
3.4.5. Genito-urinary cancers
Recommendations concerned mainly prostate, bladder
and kidney cancers. In summary, the French recom-
mendations [12,38] for prostate cancer are oriented to-
wards delaying all RT planning by 3e6 months. During
this period, ADT administration is recommended in
intermediate and high-risk patients. For RT, schedules
should be hypofractionated if RT is started during the
COVID-19 period [39,40]. For low-risk patients, surgery
could be delayed in favour of active surveillance.
Moreover, surgery should not be delayed more than two
months in high-risk and locally advanced patients [12].
This will be considered in accordance with the avail-
ability of operating rooms and the post-operative com-
plications risk.
In patients with bladder cancer, surgery should not be
delayed more than three months in the majority of cases.
When RT is indicated, it should be hypofractionated.
Primary chemotherapy and number of cycles should be
discussed on a case-by-case basis. If surgery is preferred,
a maximum of three months after diagnosis is proposed
[12].
For the kidneys, beside locally advanced and
thrombosis situations, surgery has to be delayed after
confirmation in the tumour board [12].
3.4.6. Gastrointestinal cancer
In summary, surgery could be postponed by three
months for gastrointestinal (GI) cancers when other
therapies are indicated. All decisions should be taken in
accordance with the stage of the disease and the risk of
spread in case of delaying optimal therapy [25].
Oesophagus cancer should be treated whenever
possible with RT and concomitant carboplatin and
taxol. In the neoadjuvant setting or salvage therapy,
surgery could be delayed up to three months [40,41].
Detailed RT recommendations, including definitivecombined radiochemotherapy and fractionation have
been reported by Jones et al. [26]. They also suggested
that as the impact of RT on disease severity in patients
with a diagnosis of COVID-19 is unknown and it may
be appropriate to avoid RT in such patients.
Surgery for rectal cancer should be delayed up to
three months [40] and neoadjuvant treatment for new
patients should be carried out with the short-course
scheme [40,42], reserving the classical CAP50 therapy.
The watch and wait attitude is possible for patients with
complete response after standard chemo-RT [40,43,44].
In anal canal carcinomas, chemo-RT capecitabine
should replace 5-FUþ/- mitomycin C[40,45]. Brachy-
therapy, if indicated, could be delayed [39].
For pancreatic and other GI cancers, ESMO guide-
lines defined high priorities for surgery and systemic
therapy [46,47]. All resectable cancers and borderline
patients who are not fit for neoadjuvant chemotherapy
should be considered as high priority. In locally
advanced disease, initiation or completion of neo-
adjuvant chemotherapy when already started or patients
included in clinical trials should be also considered as a
high priority [47].4. Discussion
This review aims to summarize some national/interna-
tional guidelines and literature regarding the organiza-
tion of patient management and specific
recommendations by tumour sites. Indeed, outbreaks of
COVID-19 disease may result in the interruption of
medical care provided to patients with cancer and
induce undertreatment in addition to the risk of infec-
tion and death from COVID-19. Early data from China
and Italy suggest that patients with cancer may be at
higher risk of contracting COVID-19, particularly when
multiple visits are needed, and also developing more
severe forms of the disease [48,49]. One prospective
study on 1590 patients pointed out the higher incidence
of COVID-19 in patients with cancer [49]. In addition,
patients with cancer seem to be at a greater risk of
ventilation need and death [50,51]. Thus, preventing
patients with cancer from being exposed to COVID-19
is a critical public health priority that needs an impor-
tant effort in terms of staff and department organization
and patient screening to adapt therapy delay and man-
agement despite COVID-19 infection risk. The benefit
risk/ratio is a key point for all newly diagnosed cancers,
as delaying treatment is not recommended if, at all,
avoidable [28,52].
In LMICs the problem of delay in diagnosis already
exists. So the fear with the COVID-19 pandemic is to see
an increase in the number of patients with locally
advanced cancers who do not receive treatment in time.
In certain countries, with the screening program being
stopped during the pandemic, locally advanced forms
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suspended for a long time. For head and neck cancers
for example, a panel from ASTRO and ESTRO have
published statement with two pandemic scenarios: early
(risk mitigation) and late (severely reduced RT re-
sources) and treatment recommendations for five head
and neck cases. There was agreement (or strong agree-
ment) across a number of practice areas including:
treatment prioritization, whether to delay initiation or
interrupt RT [27].
In the last three months, a number of scientific soci-
eties, oncology groups and experts’ networks have sug-
gested that all efforts should be made to prevent patients
with cancer from being exposed to COVID-19. They
also proposed several recommendations for urgent new
organization in oncology departments with possible
patient selection, treatments and schedules tailored in
accordance with patients and tumour criteria, so as to
continue to provide adequate strategy for the majority
of patients [1,2,7,11,16].
In accordance with the local health system organi-
zation and tools availability, different approaches have
been undertaken by cancer centres and oncologists in
countries with early epidemics, in response to the risk of
infection, as well as strain on health systems. The main
proposals are summarized in Tables 2 and 3. They are as
follows:
(i) Minimizing the risk of exposure for patients (with a clear
policy of screening before appointments) and staff (with
daily temperature screening) to protect the immune
compromised patients.
(ii) Department reorganization with minimizing patient
turnover times (‘fast track’ area) and number of visits to
the hospital. Use of telemedicine and phone calls for
postponed appointments and non-urgent surgeries or
other treatments [53,54].
(iii) Delaying locoregional therapy data to reduce risk of
COVID-19 in patients with cancer are limited. The
American College of Surgeons recommends balancing
the risk of delay of an elective surgery with the potential
likelihood for a post-operative need for respirator utili-
zation [54]. In addition, patients with a history of sur-
gical resection may have continued immunosuppression
or other prolonged effects of surgery, which can
contribute to COVID-19 risk [55].
(iv) Shortening RT duration and plan recalculations for
hypofractionated schedules have been proposed in
accordance with the type of cancer and curative or
palliative intent situations. In some cases (e.g., low-risk
breast and prostate cancers), endocrine therapy is
advocated to delay RT by 2e4 months [3,38,39].
(v) Switching patients from intravenous to oral therapies to
limit the number of inpatient visits has been recom-
mended in France [1] and Italy [52]. In all cases, delaying
systemic therapy is not recommended if at all avoidable
[52]. For patients already in deep remission (stable for
more than 6e12 months), stopping treatment may be an
option [1,2,35].The vast majority of the published recommendations
for department organization, staff and patients’ ap-
pointments/visits are quite feasible in the majority of
LMICS. At times, there may be complex geographic
situations, unavailability of equipment or means of
communication (telemedicine) and staff which can
negatively impact the situation. The selection of patients
for whom care can be deferred becomes a major issue in
the organizational management of the weeks in which
the contagiousness to COVID-19 is high. However, the
definition of priorities can be complicated to do in
certain LMICs. For example, the NICE recommenda-
tion says that during COVID-19 pandemic ‘use RT only
id unavoidable’ [28]. This could be in agreement with the
availability of resources and means in LMICs unlike
others [28e32] are more precise in terms of patients’
selection that takes into account cancer type and disease
stage to not compromise the prognosis.
Table 4 summarizes the main recommendations by
tumour sites. There is mainly a deal between avoiding
COVID-19 contamination for patients without making
them lose chances of cure due to deferring or suspending
standard effective treatment. Even if limited evidence
exists on the modification of treatment plans to reduce
the risk of COVID-19 in patients with cancer, these
recommendations are an important support for many
oncologists to help with the decision. Adapted to the
local situation, they can also serve as a basis for de-
cisions in LMICs. However, we must note the fact that,
in addition to the limited means in some countries, the
local epidemiological context can limit these recom-
mendations applicability. One example is combined
radio chemotherapy for oesophageal cancers. In case of
unavailable modern techniques in these countries that
could ovoid significantly organ at risk exposure,
ovoiding RT has been suggested as an option as the
disease severity expected in patients with a diagnosis of
COVID-19 is unknown [26].
For surgery scheduling, the American College of
Surgeons recommends balancing the risk of delay of an
elective surgery with the potential likelihood for post-
operative ICU or respirator use [54]. Presumably, in
certain LMICs, oncological surgery continues to be
carried out in general surgery departments which are
very widely transformed into UCI during the COVID-
19 crisis. Thus, this transformation necessary to take
care of patients with COVID-19 with respiratory
distress directly impacts the cancellation of oncological
surgery.
Whatever the type of cancer, the consensus is to
postpone surgery. The most obvious cases concern those
who benefit from screening, such as breast and prostate
cancer. The recommended delay can go up to 2e3
months. However, patients’ selection for delaying sur-
gery is a crucial point, as delayed oncologic surgeries
may lead to disease progression and result in tumours
that are no longer resectable, leading to worse survival
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tients, neoadjuvant therapies represent a solution before
undergoing surgery in breast and some GI cancers
[12,38]. The dilemma in this case is to weigh the risk/
benefit ratio of treating patients optimally during the
COVID-19 period with the consequences of immuno-
suppression [55,56] and repeated visits to the hospital to
receive RT when it is indicated for combined therapy.
The delay between the end of pre-operative treatment
and surgery can also be lengthened in many cases, such
as rectal [43], endometrial [36] and bladder cancer
[12,38].
In addition, prior RT, the primary treatment, can
constitute a “waiting” solution during the COVID-19
period. The recommendations are fairly unanimous for
high-risk and locally advanced prostate cancers
[12,38,39]. Indeed, as the radiohormonotherapy trials of
prostate cancer have all used schemes with a primary
hormone therapy between 2 and 6 months before RT, it
is easier to defer the RT (up to 6 months) without any
prejudice for the patient [38,39]. Recently, Zaorsky et al.
[23] have to establish recommendations and a frame-
work by which to evaluate prostate RT management
decisions. They concluded that the Remote visits, and
Avoidance, Deferment, and Shortening of RT frame-
work can be applied to prostate cancers and other dis-
ease sites to help with decision-making in the COVID-19
pandemic. This concept could applicable in LMICs with
however some specificities regarding local situations of
health care and means.
For breast cancer, the data are less robust for pri-
mary endocrine therapy while ‘waiting’ for RT. How-
ever, the consensus recommends in many situations to
postpone or even omit RT in elderly patients with low
risk, as no evidence of impact on survival has been
demonstrated in this subset of patients [35].
RT hypofractionation, already largely used in
LMICs, is systematically recommended in the adjuvant
setting without chemotherapy. A recent report from
USA has pointed out the evidence-based guidelines for
omitting or abbreviating breast cancer RT, where
appropriate, in an effort to mitigate risk to patients and
optimize resource use [29].
In breast and prostate cancer, high evidence of
equivalence between standard and hypofractionation
has been demonstrated in the literature. However, in
prostate and breast cancer, this is generally true only for
limited irradiation volume in patients without extended
nodal RT. Large volume of lung RT could increase the
risk of lung damage if the patient became infected by
COVID-19 during RT and developed severe respiratory
acute syndrome [57].
For systemic therapies, there is currently no evidence
to support changing chemotherapy and immunotherapy
regimens. In addition, delaying treatment is not rec-
ommended if at all avoidable [52]. However, some reg-
imens can be altered to minimize infusion visits. fFor allcytotoxic regimens, dose intensity is important and
multiple studies report poorer survival in cases of dose
intensity reduction. In the surgical consensuses, the
option of an increased number of cycles allowing a
surgery delay of 2e6 weeks is advocated [12,33]. How-
ever, this should be carried out with caution regarding
treatment efficacy and its potential toxicity. In cases of
systemic therapy maintenance, switching IV to oral
therapies largely available in LMICs, is mostly recom-
mended to limit the number in-patient visits to the
hospital. For patients already in complete remission,
stopping or delaying treatment may be an option. The
use of systemic treatments is not contraindicated during
the COVID-19 pandemic period. However, given the
risk of possible immunosuppression, it is important to
discuss the indications and to prioritize the treatment
strategies in accoradance with the benefit-risk ratio as
this has been underlined in the various reference systems
cited previously [46,47,52].5. Conclusion
The COVID-19 pandemic has and will have a major
impact on the organization of healthcare systems. While
novel vaccines and drugs that target SARS-CoV-2 are
under development, the challenge for oncology com-
munity is to continue to provide the best therapy to all
patients. It will be crucial to consider the benefit risk
ratio for optimal anti-cancer therapy (to minimize the
risk of care opportunity loss for patients) and minimize
COVID-19 contaminations during therapy that may
interrupt or delay therapy, and thus, compromise pa-
tients’ outcome. Several recommendations published
from the early period of the crisis have helped for urgent
new organization in oncology departments with possible
patient selection, treatments and schedules tailored ac-
cording to patients and tumour criteria.
In LMICs, the challenge is to define strategies to
try mitigating the deleterious effect of COVID-19
pandemic on cancer care. These negative effects will
be probably amplified due to (i) epidemiology of
cancer diagnosed in more advanced stages in these
countries, (ii) limited means for diagnostic and treat-
ment that will delay cancers management; (iii) the
need to manage COVID-19 patients in limited number
of centres that will impose delay for cancer therapy
and (iv) the economic impact of the COVID-19
pandemic on health system priorities and investment
in oncology.
Of note, the vast majority of these recommendations
for department organization, are quite feasible in the
majority of LMICs where the context for cancers pa-
tients is related multiple parameters such as: late diag-
nosis, long waiting lists for therapy and the lack of
therapeutic innovations due to the economic situation
which may be worsened by the COVI-19 pandemic.
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